Liver Cancer Clinical Trial
Official title:
Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
To develop a real-time diagnostic technique with e- Ab sensor for specific LECT2 detection in clinical specimens of Hepatocellular carcinoma (HCC) patients, the investigators conduct a prospective clinical study. In comparison with results from direct sequencing of LECT2, the investigators evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction. With such technique, the investigators can obtain LECT2 information of HCC patients in cost-saving and time-saving way and can offer more individualized treatment for our patients.
Hepatocellular carcinoma (HCC) is one of the most common types of cancer in the world. High
cancer recurrence is still the major cause of death of HCC patients. The major poor
prognostic factors included vascular invasion, high α-FP, large tumor size, or tumor
satellitosis, etc. Among the various literature reports with multivariate analysis, vascular
invasion of the tumor is the major contribution of high recurrence and poor survival.
Therefore, identifying differentially expressed genes between vascular-invasion and
non-vascular invasion of HCCs is important.
After suppression subtractive hybridization and microarray experiments, the investigators
identified 20 differentially-expressed genes between vascular-invasive, and non-vascular
invasive HCCs. One of the most interesting gene is leukocyte cell-derived chemotaxin 2
(LECT2). Further evaluation of the role of LECT2 on HCCs, the investigators found (1) Higher
invasiveness, the lower of LECT2 gene expression in the HCC cell lines. (2) Conditioned
medium with high LECT2 content will inhibit HCC invasion. (3) The invasion ability decreased
in LECT2-overexpression hepatoma cell line. (4) In transendothelial cell migration assay,
the investigators could observed invasion ability increased when LECT2 was knockdown in HCC
cell line. (5) The lower expression of LECT2 gene in human HCCs correlate with higher tumor
stage, early recurrence, and poor prognosis. (6) In vivo experiments revealed LECT2 can
inhibit the ability of intravasation or metastatic ability of HCC.
Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and
sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used
for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2
with liver cancer) present in the specimens of patients with liver cancer. The system
incorporates the use of engineered semiconductive antibodies or virus in vertical and
lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing
antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe,
which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the
test specimens. From assessment of the electric signature of semiconductive
mutation-specific anti-LECT2 antibodies, the eABprobe could offer sensitive detection and
precise quantification of specific LECT2.
To develop a real-time diagnostic technique with e- Ab sensor for specific LECT2 detection
in clinical specimens of HCC patients, the investigators conduct a prospective clinical
study. The investigators evaluate the performance of e- Ab sensor, including
reproducibility, sensitivity, specificity, and cross-reaction. With such technique, the
investigators can obtain LECT2 information of HCC patients in cost-saving and time-saving
way and can offer more individualized treatment for our patients.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Recruiting |
NCT05160740 -
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
|
N/A | |
Completed |
NCT01906021 -
Study of New Software Used During Ablations
|
N/A | |
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Enrolling by invitation |
NCT04466124 -
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT03059238 -
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
|
Phase 3 | |
Recruiting |
NCT02632188 -
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00980239 -
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
|
Phase 1 | |
Completed |
NCT01042041 -
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
|
Phase 1 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00543777 -
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00888407 -
Community-based Hepatitis B Interventions for Hmong Adults
|
N/A |